Healthcare - Biotechnology - NASDAQ - US
$ 9.17
-12.6 %
$ 626 M
Market Cap
-4.61
P/E
CASH FLOW STATEMENT
1.88 M
OPERATING CASH FLOW
-3.32 M
INVESTING CASH FLOW
187 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
EyePoint Pharmaceuticals, Inc.
| Net Income | -70.8 M |
| Depreciation & Amortization | 464 K |
| Capital Expenditures | -3.48 M |
| Stock-Based Compensation | 12.1 M |
| Change in Working Capital | 58.9 M |
| Others | 45.7 M |
| Free Cash Flow | -1.61 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Jun-2018 | Jun-2017 | Jun-2016 | Jun-2015 | Jun-2014 | Jun-2013 | Jun-2012 | Jun-2011 | Jun-2010 | Jun-2009 | Jun-2008 | Jun-2007 | Jun-2006 | Jun-2005 | Jun-2004 | Jun-2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||||||||||
| Net Income | (70.8) | (102.3) | (58.4) | (45.4) | (56.8) | (53.2) | (18.5) | (21.5) | 6.3 | (13.4) | (11.9) | (24.8) | (8.6) | 8.8 | (2.5) | (75.7) | (103.7) | (20.9) | (11.5) | (5.2) | (3.6) |
| Depreciation & Amortization | 0.5 | 2.4 | 2.8 | 2.6 | 2.6 | 1.1 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 | 2.2 | 3.4 | 3.3 | 3.4 | 0.4 | 8.7 | 8.7 | 1.2 | 0.2 | 0.2 |
| Deferred Income Tax | 83 K | 0 | (0.8) | 0.9 | 3.8 | 26.3 | 0 | 0 | 0 | 78 K | 0 | 13 K | (0.2) | 1 K | 94 K | (0.5) | (23.5) | (7.1) | 0 | 0 | 0 |
| Stock Based Compensation | 12.1 | 14.2 | 7.4 | 5.5 | 4.6 | 4.0 | 2.7 | 2.5 | 2.2 | 2.0 | 1.4 | 1.3 | 1.4 | 2.1 | 1.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Operating Activities | 1.2 | 23.6 | 0.6 | 1.7 | 1.6 | 0.2 | (5.6) | 87 K | 98 K | 45 K | 0.2 | 14.9 | (1.0) | 0.3 | 0.3 | 57.2 | 92.3 | 1.5 | 1.2 | (1.0) | 67.2 K |
| Change in Working Capital | 58.9 | (3.0) | (1.7) | 20.1 | (12.5) | 0.9 | 0.3 | 2.1 | 1.0 | 0.4 | 0.7 | (2.7) | 1.2 | (4.0) | (10.5) | 13.5 | 0.1 | 2.2 | (0.3) | 0.6 | 0.3 |
| Cash From Operations | 1.9 | (65.0) | (50.1) | (14.4) | (56.7) | (21.9) | (20.5) | (16.3) | 10.3 | (10.7) | (8.7) | (9.0) | (3.2) | 9.9 | (8.4) | (5.1) | (21.2) | (16.1) | (9.3) | (5.4) | (3.1) |
| INVESTING CASH FLOW | |||||||||||||||||||||
| Capital Expenditures | (3.5) | (2.1) | (0.2) | (0.4) | (0.2) | (0.1) | (0.1) | (0.1) | (0.2) | (0.2) | 68 K | (0.4) | (0.1) | 15 K | (0.2) | (0.3) | 82 K | (1.2) | (2.6) | (0.4) | 35.6 K |
| Other Items | 0.2 | (15.1) | (33.0) | 0 | 0 | (16.8) | 13.7 | (4.3) | (6.6) | 0.3 | 6.4 | 1.0 | (9.4) | (2.1) | 0 | 13 K | 1.9 | (3.0) | (3.5) | 0 | 677 |
| Cash From Investing Activities | (3.3) | (17.3) | (33.1) | (0.4) | (0.2) | (16.9) | 13.6 | (4.5) | (6.7) | 66 K | 6.4 | 0.6 | (9.5) | (2.1) | (0.2) | (0.3) | 1.8 | (4.1) | (6.1) | (0.4) | 34.9 K |
| FINANCING CASH FLOW | |||||||||||||||||||||
| Common Stock Repurchased | (0.2) | (0.3) | 0 | 0 | 0 | (0.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (2.2) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (30.0) | 2.1 | (0.1) | (11.8) | 30.0 | 20.0 | 20.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (13.3) | 14.4 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.1) | (2.5) | 0.2 | (0.6) | (18.8) | (20.2) | (0.8) | 99 K | 0.5 | 0.2 | 1.0 | 0 | 0.1 | 17 K | 0.8 | 18.4 | 0 | 7.5 | (1.7) | 20.8 K | 0.3 |
| Cash From Financing Activities | 187.1 | (0.7) | 216.9 | 37.5 | 33.9 | 60.7 | 8.5 | 17.0 | 0.2 | 19.0 | 4.7 | 0.1 | 10.1 | 0.8 | 0.8 | 18.4 | 10.1 | 21.7 | 2.8 | 25.7 | 0.6 |
| CHANGE IN CASH | |||||||||||||||||||||
| Net Change In Cash | 185.6 | (83.0) | 133.7 | 22.7 | (23.0) | 21.9 | 1.6 | (3.8) | 3.8 | 8.4 | 2.3 | (8.3) | (2.6) | 8.6 | (8.7) | 12.9 | (10.4) | 1.9 | (14.0) | 21.0 | (2.6) |
| FREE CASH FLOW | |||||||||||||||||||||
| Free Cash Flow | (1.6) | (67.2) | (50.3) | (14.8) | (56.9) | (22.0) | (20.6) | (16.4) | 10.1 | (10.9) | (8.8) | (9.4) | (3.3) | 9.9 | (8.6) | (5.4) | (21.3) | (17.3) | (11.9) | (5.8) | (3.1) |